Flexible Solutions Intl Q2FY26 Results: Net loss hits $1.91 million

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Net loss widened to $1.91 million in Q2FY26 from a $2.03 million profit in Q2FY25
  • Revenue fell 14% YoY to $7.60 million, impacted by absence of $2.5 million irregular R&D income
  • Recurring revenue grew year-over-year when excluding non-recurring items
  • Company regained exclusive rights to Florida LLC products, targeting $5-7 million annual recovery
  • Return to profitability expected in Q3FY26 as food-grade contracts scale up
powered bylight_fuzz_icon
51281588

*this image is generated using AI for illustrative purposes only.

Flexible Solutions International (AMEX: FSI) reported a second-quarter 2026 net loss of $1.91 million, a sharp reversal from the $2.03 million profit recorded in the same period of FY25. The decline was driven by a 14% drop in sales to $7.60 million, primarily due to the absence of $2.5 million in irregular R&D revenue from the prior year and costs associated with scaling food-grade operations.

Financial Performance

The company’s top-line contraction reflects both structural shifts and one-off factors. While total sales fell to $7.60 million from $8.87 million in Q2 2025, management noted that recurring revenue actually increased year-over-year when excluding the non-recurring R&D fees. The bottom-line impact was severe, with the company posting a loss of $0.15 per share compared to earnings of $0.16 per share last year.

Metric Q2FY26 Q2FY25 Change
Revenue $7.60 million $8.87 million -14%
Net Profit/Loss ($1.91) million $2.03 million Turned to Loss
EPS ($0.15) $0.16 N/A

The loss was attributed to expensed costs for scaling up food-grade contracts announced in January and August 2025, as well as ongoing setup expenses for the Panama factory. These operational expenditures outpaced revenue generation in the quarter, preventing profitability despite improved efficiency in certain divisions.

What the Numbers Show

The divergence between the headline revenue decline and the underlying recurring revenue growth highlights the volatility of Flexible Solutions’ income streams. With $2.5 million of the prior year’s revenue classified as irregular R&D activity, the core business appears stable or growing. However, the inability to convert this recurring base into profit during Q2 underscores the heavy upfront capital and labor intensity required for the new food-grade contracts, which are currently operating at lower margins than preferred to secure tariff and inflation protections.

Divisional Updates

The NanoChem Division is transitioning fully to food-grade products by the end of 2026. Two major contracts are key to this shift: a five-year agreement with a minimum annual revenue of $6.5 million has reached full production, while a larger contract began volume production late in Q2. Management expects significant revenue visibility from the latter in Q3, with rapid increases anticipated in Q4. Margins for these large contracts are targeted at 22-25% before tax, lower than historical levels but secured with inflation protections.

The Panama Division, which produces thermal polyaspartic acid (TPA), saw increased production in Q2 but faced headwinds from poor performance by a Florida LLC customer and weak agricultural sales. However, Q3 results have improved as the company began selling directly to Florida LLC customers and capturing legacy NanoChem orders. The Panama facility offers strategic advantages, including reduced shipping times and no exposure to US tariffs on international sales.

The EMP Division, focused on greenhouse and turf markets, experienced a weak Q2 due to agricultural market pressures, including low crop prices and high input costs. Management anticipates a rebound in Q3, though the sector remains under extreme pressure from tariff changes and energy cost volatility.

Strategic Developments

Following the failure of an acquirer to fund payments for a 30.1% equity stake in the Florida LLC sold in August 2024, Flexible Solutions regained perpetual exclusive rights to four agricultural products and their IP in Latin America and the Caribbean. The company estimates a revenue recovery of $5 million to $7 million annually over the next 12 months from these rights, with initial progress already evident in Q3 orders.

Regarding balance sheet strength, the company continues to pay down long-term debt, retaining only one small term loan and a mortgage on its Illinois factory. Working capital is deemed adequate, supported by credit lines with Stock Yards Bank. Management stated confidence in executing plans without equity actions, though a shelf prospectus remains available for potential acquisitions.

Looking ahead, Flexible Solutions expects a return to profitability in Q3 2026, followed by increasing profits in Q4 as major contracts reach full production. However, risks persist from unstable shipping costs and raw material prices driven by geopolitical tensions, potentially necessitating price increases in the latter half of the year.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might the lower 22-25% target margins on new food-grade contracts impact Flexible Solutions' long-term return on invested capital compared to historical performance?

What specific operational milestones must the Panama facility achieve in Q3 and Q4 to offset the headwinds from weak agricultural sales and validate the direct-to-customer strategy?

Could the resurgence of $5 million to $7 million in annual revenue from regained Latin American IP rights accelerate the company's path to profitability beyond the projected Q3 timeline?

like20
dislike

Flexible Solutions appoints Dr. Kim Reid as director and audit committee member

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Flexible Solutions appoints Dr. Kim Reid as director and audit committee member
  • John Bientjes resigns after nearly thirty years; David Fynn becomes audit committee chair
  • Dr. Reid brings bio-manufacturing expertise and GMP training to the board
  • Company focuses on biodegradable polymers for oil, water treatment, and crop enhancement
powered bylight_fuzz_icon
49754220

*this image is generated using AI for illustrative purposes only.

Flexible Solutions International, Inc. (NYSE-AMERICAN: FSI) appointed Dr. Kim Reid as a director and audit committee member effective immediately. The board also announced the resignation of John Bientjes after nearly thirty years of service.

Dr. Reid will serve until the next annual meeting. She brings extensive experience in bio-manufacturing, molecular biology, and operational leadership. Currently a postdoctoral fellow at the Ottawa Hospital Research Institute, she leads technology transfer efforts for mRNA-LNP cancer-vaccine production.

Board Composition Changes

John Bientjes resigned from the board after nearly three decades. He previously served as audit committee chair. David Fynn, a long-standing audit committee member, assumed the chair position.

Dr. Reid’s background includes specialized training in GMP and mRNA biomanufacturing. Her research appears in peer-reviewed journals including Scientific Reports and the Journal of Biological Chemistry. She previously served as an officer and fighter pilot with the Royal Canadian Air Force.

New Director Profile

Dr. Reid holds a PhD in Biology from the University of Ottawa. She also possesses an MSc in Experimental Pathology and Laboratory Medicine from UBC. Her professional history includes founding the Expert Talk Series for the Society for RNA Therapeutics.

The company stated her experience will contribute to board discussions on technology, innovation, risk, and regulated environments.

Company Overview

Based in Taber, Alberta, Flexible Solutions develops biodegradable polymers for oil extraction, detergent ingredients, and water treatment. Its subsidiary, NanoChem Solutions Inc., manufactures thermal polyaspartate (TPA) biopolymers.

In 2022, the company entered the food and nutrition markets after obtaining FDA food-grade approval for its Peru IL plant. The firm also produces energy and water conservation products for industrial and agricultural sectors globally.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How will Dr. Reid's expertise in mRNA-LNP production influence Flexible Solutions' strategy for expanding its biopolymer applications into the pharmaceutical or vaccine delivery sectors?

What specific operational or compliance risks might arise from the transition of audit committee leadership from John Bientjes to David Fynn, and how will the board ensure continuity?

Given Dr. Reid's background in regulated environments, how might her appointment accelerate the company's regulatory approvals for its newly entered food and nutrition markets?

like15
dislike

More News on Flexible Solutions International Inc